Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9 Neoplasms 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Stomach Neoplasms 2 Solid Tumors 1 Solid Cancers 1 Skin Diseases 1 Ovarian Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Breast Diseases 1 Advanced Unresectable or Metastatic Solid Malignancy 1 Adenocarcinoma 1

Interventions

Gemcitabine 27 Fluorouracil 25 Oxaliplatin 21 Cisplatin 19 Leucovorin 17 Bevacizumab 16 Docetaxel 13 Albumin-Bound Paclitaxel 13 130-nm albumin-bound paclitaxel 13 Paclitaxel 12 Capecitabine 12 Irinotecan 11 Carboplatin 9 pembrolizumab 7 Nivolumab 7 Radiotherapy 6 Pemetrexed 6 Erlotinib Hydrochloride 6 Cyclophosphamide 6 Trastuzumab 5 Ramucirumab 5 Ipilimumab 4 Everolimus 4 Crizotinib 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × ipatasertib × Clear all

NCT04739202 2026-06-09

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡